Liquid biopsy firm Thrive launches with $110M Series A round
The company has a 10,000-patient prospective trial with Geisinger fully enrolled to test CancerSEEK, a test developed at Johns Hopkins University.
Verve Therapeutics aims to tackle heart disease through gene editing
The company, partnered with Beam Therapeutics, Verily Life Sciences and academic institutions, plans to use gene editing to tackle coronary artery disease. However, experience with gene therapy indicates cost could be a hurdle.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Two new venture funds, two new women at the top
Welcome to the senior VC club. Julie Sunderland of Biomatics Capital and Tracy Saxton of Pivotal bioVenture Partners closed their first funds this week, bringing fresh perspectives to the life science investment game.